Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049675 | 0.84 | KMT2A (0.44) | PRMT5WDR77DRD2DRD4DRD3 | |
| SCHEMBL24002403 | 0.83 | KAT6A (0.41) | PRMT5WDR77KMT2ALMNAALDH1A1 | |
| SCHEMBL25754063 | 0.81 | PRMT5 (0.37) | PRMT5WDR77DRD2DRD4DRD3 | |
| SCHEMBL26010490 | 0.81 | ALDH1A1 (0.35) | PRMT5WDR77KMT2ALMNAALDH1A1 | |
| SCHEMBL24002293 | 0.81 | GAA (0.41) | PRMT5WDR77DRD2DRD4DRD3 | |
| SCHEMBL22598236 | 0.80 | ALDH1A1 (0.34) | PRMT5WDR77KMT2ALMNAALDH1A1 | |
| SCHEMBL22598392 | 0.80 | ALDH1A1 (0.34) | PRMT5WDR77KMT2ALMNAALDH1A1 | |
| SCHEMBL22327122 | 0.80 | ALDH1A1 (0.34) | PRMT5WDR77KMT2ALMNAALDH1A1 | |
| SCHEMBL22327238 | 0.76 | KAT6A (0.40) | KMT2ALMNAALDH1A1L3MBTL1GAA | |
| SCHEMBL24402175 | 0.76 | ALDH1A1 (0.43) | DRD2DRD4DRD3KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | PRMT5 3226/4885WDR77 2188/4885DRD2 3700/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | PRMT5 3226/4885WDR77 2188/4885DRD2 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.